Target intelligence / Profile preview

Influenza A virus hemagglutinin (H5 subtype, clade 2.3.4.4b, B1 lineage) (H5 HA (B1 lineage))

Target
H5 HA (B1 lineage)
Molecular classification
Viral surface glycoprotein, Class I fusion protein, Receptor
01

Overview

Influenza A virus hemagglutinin (HA) is the primary surface glycoprotein responsible for viral entry into host cells. The H5 subtype, particularly within clade 2.3.4.4b, has gained significant global attention due to its high pathogenicity in avian species and its recent spillover into various mammals, including cattle and humans. The B1 lineage is a specific phylogenetic sublineage of the H5 HA gene that emerged and began co-circulating with the B2 lineage around 2021, primarily in Europe and North America. HA functions by binding to sialic acid receptors on the host cell surface and subsequently mediating the fusion of the viral envelope with the endosomal membrane under acidic conditions. As the major antigen of the virus, it is the primary target for seasonal and pandemic vaccines, as well as for the development of broadly neutralizing antibodies. Therapeutic strategies targeting this molecule aim to block viral attachment or fusion, thereby preventing infection and reducing disease severity.

Other names
H5 hemagglutininH5 HAClade 2.3.4.4b B1 lineage HAHPAI H5N1 B1 lineage hemagglutininInfluenza A virus H5N1 hemagglutinin
02

Mechanism of action

Inhibition of viral attachment to host sialic acid receptors, inhibition of pH-dependent membrane fusion, and neutralization of viral infectivity through antibody binding to the HA head or stem domains.

03

Biological functions

Viral attachmentMembrane fusionSialic acid bindingHost cell entry
04

Disease associations

InfectionAvian influenza (H5N1)Highly Pathogenic Avian Influenza (HPAI)Zoonotic infectionPandemic potential
05

Safety considerations

Antigenic drift leading to immune evasionPotential for genetic reassortment and pandemic emergenceHigh pathogenicity and mortality in human zoonotic casesVaccine mismatch due to rapid evolution of clades
06

Interacting drugs

Audenz (H5N1 monovalent vaccine)

3 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HI) titersMicroneutralization (MN) titersHA gene clade sequencingViral load (RT-PCR)

Beyond the preview

Go deeper on Influenza A virus hemagglutinin (H5 subtype, clade 2.3.4.4b, B1 lineage) (H5 HA (B1 lineage)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus hemagglutinin (H5 subtype, clade 2.3.4.4b, B1 lineage) (H5 HA (B1 lineage)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call